A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris

In the continued absence of an effective anti-HIV vaccine, approximately 2 million new HIV infections occur every year, with over 95% of these in developing countries. Calls have been made for the development of anti-HIV drugs that can be formulated for topical use to prevent HIV transmission during...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerini, Fabrice, Gaertner, Hubert, Madden, Knut, Tolstorukov, Ilya, Brown, Scott, Laukens, Bram, Callewaert, Nico, Harner, Jay C., Oommen, Anna M., Harms, John T., Sump, Anthony R., Sealock, Robert C., Peterson, Dustin J., Johnson, Scott K., Abramson, Stephan B., Meagher, Michael, Offord, Robin, Hartley, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Press 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725576/
https://www.ncbi.nlm.nih.gov/pubmed/26506568
http://dx.doi.org/10.1016/j.pep.2015.10.011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725576/
https://www.ncbi.nlm.nih.gov/pubmed/26506568
http://dx.doi.org/10.1016/j.pep.2015.10.011

Ejemplares similares